title: Incidence of diabetes in patients with schizophrenia: a population-based study.
abstract: OBJECTIVE
  To detect the incidence of diabetes in patients with schizophrenia in Taiwan.
  
  
  METHODS
  The National Health Research Institute provided a database of 1 million random subjects for study, from which we drew a random sample of 617 068 subjects aged 18 years and older in the year 2000. Subjects who had at least one service claim during this year, with a primary diagnosis of schizophrenia, diabetes, or with a prescription for treatment of diabetes, were identified. We compared initial diagnosis of diabetes between patients with schizophrenia and the general population in 2000. We also followed a cohort of subjects with schizophrenia from 2000 to 2005.
  
  
  RESULTS
  The incidence of diabetes was higher in patients with schizophrenia than in the general population (1.46% and 1.12%, respectively; OR 1.47; 95% CI 1.09 to 1.97) in 2000. Compared with the general population, patients with schizophrenia showed a higher incidence of diabetes in the group aged 18 to 29 years; among females; among those with insurance of more than US$1281; among those living in the northern region; and among those residing in urban areas. The average annual incidence of diabetes in patients with schizophrenia was 1.84% from 2000 to 2005. Higher incidence of diabetes in patients with schizophrenia was associated with increased age, females, hypertension, and hyperlipidemia.
  
  
  CONCLUSIONS
  Patients with schizophrenia had a higher incidence of diabetes for the youngest adult age group and for females than for the general population. Increased age, females, hypertension, and hyperlipidemia were risk factors of diabetes in patients with schizophrenia.
authors.affiliation: Department of Health, Chia-Yi Hospital, Chiayi, Taiwan.
authors.forename: Jer-Hwa
authors.initials: JH
authors.lastname: Hsu
authors.forename: I-Chia
authors.initials: IC
authors.lastname: Chien
authors.forename: Ching-Heng
authors.initials: CH
authors.lastname: Lin
authors.forename: Yiing-Jenq
authors.initials: YJ
authors.lastname: Chou
authors.forename: Pesus
authors.initials: P
authors.lastname: Chou
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D015897:Comorbidity; D003430:Cross-Sectional Studies; D003920:Diabetes Mellitus / Q000139:chemically induced / Q000453:epidemiology*; D005260:Female; D006306:Health Surveys; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced / Q000453:epidemiology; D006973:Hypertension / Q000139:chemically induced / Q000453:epidemiology; D015994:Incidence; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009313:National Health Programs / Q000706:statistics & numerical data; D012307:Risk Factors; D012559:Schizophrenia / Q000188:drug therapy / Q000453:epidemiology*; D013624:Taiwan; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents